

# Hematopoiesis in 5-Fluorouracil-Treated Adenosine A<sub>3</sub> Receptor Knock-Out Mice

M. HOFER<sup>1</sup>, M. POSPÍŠIL<sup>1</sup>, L. DUŠEK<sup>2</sup>, Z. HOFEROVÁ<sup>1</sup>, D. KOMŮRKOVÁ<sup>1</sup>

<sup>1</sup>Department of Molecular Cytology and Cytometry, Institute of Biophysics, Czech Academy of Sciences, Brno, Czech Republic, <sup>2</sup>Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Received June 12, 2014

Accepted August 18, 2014

On-line October 15, 2014

## Summary

The purpose of the study was to describe and compare normal and 5-fluorouracil (5-FU)-suppressed hematopoiesis in adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) mice and their wild-type (WT) counterparts. To meet the purpose, a complex hematological analysis comprising nineteen peripheral blood and bone marrow parameters was performed in the mice. Defects previously observed in the peripheral blood erythrocyte and thrombocyte parameters of the A<sub>3</sub>AR KO mice were confirmed. Compartments of the bone marrow progenitor cells for granulocytes/macrophages and erythrocytes were enhanced in the control, as well as in the 5-FU-administered A<sub>3</sub>AR KO mice. 5-FU-induced hematopoietic suppression, evaluated on day 2 after the administration of the cytotoxic drug, was found to be significantly deeper in the A<sub>3</sub>AR KO mice compared with their WT counterparts, as measured at the level of the bone marrow progenitor cells. The rate of regeneration, as assessed between days 2 and 7 after 5-FU administration, was observed in the population of the granulocyte/macrophage progenitor cells to be higher in the A<sub>3</sub>AR KO mice in comparison with the WT ones. The increased depth of 5-FU-induced suppression in the compartments of the hematopoietic progenitor cells in the A<sub>3</sub>AR KO mice represents probably a hitherto undescribed further consequence of the lack of adenosine A<sub>3</sub> receptors and indicates its synergism with the pharmacologically induced cytotoxic action of 5-FU.

## Key words

Adenosine A<sub>3</sub> receptor knock-out mice • Hematopoiesis • 5-fluorouracil-induced hematotoxicity

## Corresponding author

M. Hofer, Department of Molecular Cytology and Cytometry, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, CZ-612 65 Brno, Czech Republic.  
E-mail: hofer@ibp.cz

## Introduction

Adenosine A<sub>3</sub> receptors belong to the family of adenosine receptors that are integral membrane molecules mediating cell signaling by their purinergic ligands (e.g., Abbracchio and Burnstock 1998, Poulsen and Quinn 1998, Fredholm *et al.* 2001, Klotz 2000). Signaling through adenosine receptors was found to modulate cell proliferation, differentiation, and apoptosis (Jacobson *et al.* 1999, Schulte and Fredholm 2003).

The hematopoiesis-regulating role of adenosine receptors in general and adenosine A<sub>3</sub> receptors in particular under the conditions of their pharmacological activation has been intensively investigated by the authors (for review see Hofer and Pospíšil 2006, Hofer *et al.* 2011b). Briefly summarized, adenosine receptors can be pharmacologically activated either non-selectively, by their natural agonist adenosine, or selectively, by synthetic adenosine analogs (Jacobson 2002). We have found that non-selective activation of adenosine receptors stimulates hematopoiesis in normal and ionizing radiation-exposed mice (e.g., Pospíšil *et al.* 1992, 1993, Hofer *et al.* 1995, 1997). The ability of non-selective activation of adenosine receptors to up-regulate hematopoiesis has been shown also in conditions of

hematopoietic suppression induced by the cytotoxic drug 5-fluorouracil (e.g., Hofer *et al.* 2001).

In subsequent studies, selective stimulation of adenosine A<sub>3</sub> receptors by their selective agonist N<sup>6</sup>-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) was found to be responsible for the previously observed stimulatory action of non-selective adenosine receptor stimulation: IB-MECA was found to stimulate proliferation of hematopoietic progenitor cells (Pospíšil *et al.* 2004) and to support hematopoietic regeneration following application of cytotoxic antitumor drugs (Merimsky *et al.* 2003, Hofer *et al.* 2006) or ionizing radiation (Hofer *et al.* 2010).

Of interest were the results of a study using real-time PCR (RT-PCR) showing that adenosine A<sub>3</sub> receptors are expressed in four mouse hematopoietic precursor cells (Štreitová *et al.* 2010). The result points out that a direct stimulation of these cells with a selective adenosine A<sub>3</sub> receptor is possible. Another RT-PCR study revealed that the expression of mRNA for adenosine A<sub>3</sub> receptors on model promyelocytic HL-60 cells is dependent on the cell cycle phases (Hofer *et al.* 2011a). This finding enables us to formulate hypotheses on the mechanisms of the regulatory action of adenosine A<sub>3</sub> receptors in hematopoiesis. The studies on the expression of adenosine A<sub>3</sub> receptors in hematopoietic cells bear connection to the latest investigations summarized below.

Most recently a new insight into the topic of the regulation of hematopoiesis through adenosine A<sub>3</sub> receptors has been made possible by the utilization of adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) mice. The description and analysis of the state of hematopoiesis in individual cell compartments of the peripheral blood and the bone marrow has enabled us to reveal cell populations affected by the lack of adenosine A<sub>3</sub> receptors. Thus, defects have been described in the populations of the mouse peripheral blood erythrocytes and platelets of the A<sub>3</sub>AR KO mice (Hofer *et al.* 2013a). The succeeding studies comprising also exposition of A<sub>3</sub>AR KO mice to ionizing radiation have revealed that the defects at the level of mature peripheral blood cells are attempted to be compensated from the level of the bone marrow progenitor cells (Hofer *et al.* 2014a).

The results obtained in this communication extend the knowledge on the functioning of adenosine A<sub>3</sub> receptors in hematopoiesis. A<sub>3</sub>AR KO mice were experimentally exposed to 5-fluorouracil and the kinetics of the induced hematological damage and the subsequent regeneration were followed.

## Material and Methods

### Mice

Adenosine A<sub>3</sub> receptor knock-out (Adora<sup>tm1Jbsn</sup>/Adora<sup>tm1Jbsn</sup>, A<sub>3</sub>AR KO) male mice, backcrossed onto a C57BL/6 background (Salvatore *et al.* 2000), were obtained from Merck Research Laboratories (West Point, PA, USA) and bred in the Laboratory Animal Breeding and Experimental Facility of the Faculty of Medicine, Masaryk University, Brno, Czech Republic. Wild-type (WT) C57BL/6 mice were obtained from the Laboratory Animal Breeding and Experimental Facility of the Faculty of Medicine, Masaryk University, Brno, Czech Republic. For material sampling 2.5 months old mice were used.

### 5-fluorouracil (5-FU) administration, sampling of material

5-fluorouracil (5-FU) (Sigma, St. Louis, MO, USA) was dissolved in saline and given intraperitoneally (i.p.) in a single dose of 100 mg/kg in a volume of 0.2 ml. This dose was based on previous experimental experience (Weiterová *et al.* 2000). Sampling of material was performed on days 2 and 7 after 5-FU administration, and in untreated control mice.

### Hematological techniques

For evaluation of the peripheral blood parameters, the animals were anesthetized with an i.p. injection of 0.07 ml of Narkamon (ketamine in the form of ketamine hydrochloride)/Rometar (xylazine in the form of xylazine hydrochloride) solution (5 % Narkamon and 2 % Rometar [both Spofa, Praha, Czech Republic]) in a ratio of 2.63:1, and the peripheral blood was sampled by cardiac puncture. The numbers of total leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, erythrocytes, and platelets per 1 µl of the peripheral blood were determined by an Auto Hematology Analyzer Mindray 5300Vet (Shenzen, China). The same device was used for the determination of blood hemoglobin level (HGB), hematocrit (HCT), mean erythrocyte volume (MCV), mean erythrocyte hemoglobin (MCH), mean erythrocyte hemoglobin concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), plateletcrit (PCT), and platelet distribution width (PDW).

In mice sacrificed by cervical dislocation, the femurs were removed, marrow cells were harvested by standard procedures, and the numbers of nucleated cells of the femoral bone marrow were determined using a

Coulter Counter (Model ZF, Coulter Electronics, Luton, UK). Standard procedures were used for *in vitro* assays of the femoral clonogenic progenitor cells. Granulocyte-macrophage colony-forming cells (GM-CFC) were assessed using the MethoCult M3001 medium (StemCell Technologies, Vancouver, Canada). Erythroid progenitor cells (BFU-E) were determined using the MethoCult SF M3436 medium (Stem Cell Technologies). Femoral marrow cell suspensions were plated ( $1.5 \times 10^5$  and  $1 \times 10^5$  nucleated bone marrow cells for GM-CFC and BFU-E, respectively) in triplicate for both assays and incubated at 37 °C in a humidified atmosphere containing 95 % air and 5 % CO<sub>2</sub>. GM-CFC were scored after a 7-day incubation as colonies containing 50 or more cells. Hemoglobinized colonies were counted as BFU-E after an 8-day incubation. Considering the differences in the average body weight between the groups of mice studied (22.5 g, 21.3 g, 21.6 g, 24.6 g, 23.3 g, and 22.8 g for untreated A<sub>3</sub>AR KO mice, A<sub>3</sub>AR KO mice on day 2 after administration of 5-FU, A<sub>3</sub>AR KO mice on day 7 after administration of 5-FU, untreated WT mice, WT mice on day 2 after administration of 5-FU, and WT mice on day 7 after administration of 5-FU, respectively), the values of the bone marrow parameters were expressed as per 1 g of body weight.

#### Statistics

The values are presented as arithmetic means  $\pm$  standard errors of the means (SEM). In each parameter, the global statistical significance among the groups was assessed using one-way ANOVA. The differences between the individual experimental groups were evaluated using the Mann-Whitney test. Each experiment was performed twice. The analyses were performed on data of combined experiments after their standardization using the z-score.

For the parameters of the numbers of neutrophils and erythrocytes per 1  $\mu$ l of the peripheral blood, as well for those of the numbers of GM-CFC/femur and BFU/femur per 1 g of body weight, independent experimental series of untreated A<sub>3</sub>AR KO mice + A<sub>3</sub>AR KO mice on day 2 after the administration of 5-FU + A<sub>3</sub>AR KO mice on day 7 after the administration of 5-FU, and that of untreated WT mice + WT mice on day 7 after the administration of 5-FU + WT mice on day 7 after the administration of 5-FU were recognized, in another analysis, as blocks. These blocks of combined data from A<sub>3</sub>AR KO mice and WT mice were evaluated

on the basis of two-way ANOVA models.

Two-way ANOVA models were also used for comparison of the rates of decrease from the control state (untreated mice) to the state in mice on day 2 after the administration of 5-FU, as well as of differences in the rates of increase from the state in mice on day 2 after the administration of 5-FU and that in mice on day 7 after the administration of 5-FU between A<sub>3</sub>AR KO mice and WT mice. These statistical analyses concerned nine selected hematological parameters (see Results).

## Results

### *Peripheral blood leukocyte parameters*

The summary of findings in the peripheral blood leukocyte parameters in the A<sub>3</sub>AR KO mice and their WT counterparts is presented in Table 1. Comparisons were performed between untreated A<sub>3</sub>AR KO mice and WT mice, between A<sub>3</sub>AR KO mice and WT mice on day 2 after the administration of 5-FU, and between these two groups of mice on day 7 after the administration of 5-FU. With the exception of one comparison in the blood eosinophil count, no significant differences were observed between the A<sub>3</sub>AR KO mice and the WT mice. Since the numbers of blood neutrophils were observed to be always lower in the A<sub>3</sub>AR KO mice, the approach of comparison of their values between A<sub>3</sub>AR KO mice and WT mice, taken as blocks (see Material and Methods), was used. However, the P value reached not even under these conditions a statistical significance (0.098).

### *Peripheral blood erythrocyte parameters*

The peripheral blood erythrocyte parameters are summarized in Table 2. The blood erythrocyte count was found to be statistically higher in untreated A<sub>3</sub>AR KO mice in comparison with their WT counterparts. Since also on days 2 and 7 after the administration of 5-FU the numbers of erythrocytes were higher in the A<sub>3</sub>AR KO mice than in the WT ones, the approach of comparing these mice as blocks was used again. In this approach, the erythrocyte counts were found to be, in general, significantly higher in the A<sub>3</sub>AR KO mice (P=0.006). On the other hand, significantly lower values of MCV and MCH were observed in the A<sub>3</sub>AR KO mice in all comparisons (untreated mice, mice on day 3 after the administration of 5-FU, and mice on day 7 after the administration of 5-FU).

**Table 1.** Values of peripheral blood leukocyte parameters in untreated, 5-fluorouracil (5-FU)-treated (day 2 after treatment), and 5-FU-treated (day 7 after treatment) adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) and wild-type (WT) mice.

| Parameter   | Untreated<br>A <sub>3</sub> AR KO<br>mice<br>n=6 | Untreated<br>WT mice<br>n=6 | A <sub>3</sub> AR KO<br>mice – day 2<br>after 5-FU<br>n=9 | WT mice<br>– day 2<br>after 5-FU<br>n=9 | A <sub>3</sub> AR KO<br>mice – day 7<br>after 5-FU<br>n=8 | WT mice<br>– day 7<br>after 5-FU<br>n=8 |
|---|--|-----------------------------|---|---|---|---|
| Blood leukocyte count<br>(x 10 <sup>9</sup> /l)   | 4.8 ± 0.47                                       | 5.2 ± 0.35                  | 4.2 ± 0.67  | 3.8 ± 0.21                              | 1.9 ± 0.28  | 2.1 ± 0.17                              |
| Blood granulocyte count<br>(x 10 <sup>9</sup> /l) | 0.64 ± 0.084                                     | 0.74 ± 0.073                | 0.51 ± 0.070  | 0.61 ± 0.050                            | 0.06 ± 0.014  | 0.10 ± 0.047                            |
| Blood lymphocyte count<br>(x 10 <sup>9</sup> /l)  | 3.8 ± 0.45                                       | 4.1 ± 0.36                  | 3.6 ± 0.62  | 3.2 ± 0.21                              | 1.7 ± 0.25  | 1.9 ± 0.15                              |
| Blood monocyte count<br>(x 10 <sup>9</sup> /l)    | 0.33 ± 0.044                                     | 0.37 ± 0.065                | 0.06 ± 0.018  | 0.06 ± 0.008                            | 0.04 ± 0.006  | 0.01 ± 0.005                            |
| Blood eosinophil count<br>(x 10 <sup>9</sup> /l)  | 0.05 ± 0.019                                     | 0.09 ± 0.039                | 0.06 ± 0.036  | 0.04 ± 0.023                            | 0.01 ± 0.006*   | 0.02 ± 0.007                            |

The results are presented as arithmetic means ± standard errors of the means (SEM). n = numbers of mice. \* the value in A<sub>3</sub>AR KO mice is statistically significantly (P≤0.05) lower than that in the corresponding WT counterparts.

**Table 2.** Values of peripheral blood erythrocyte parameters in untreated, 5-fluorouracil (5-FU)-treated (day 2 after treatment), and 5-FU-treated (day 7 after treatment) adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) and wild-type (WT) mice.

| Parameter  | Untreated<br>A <sub>3</sub> AR KO<br>mice<br>n=6 | Untreated<br>WT mice<br>n=6 | A <sub>3</sub> AR KO<br>mice – day 2<br>after 5-FU<br>n=9 | WT mice<br>– day 2<br>after 5-FU<br>n=9 | A <sub>3</sub> AR KO<br>mice – day 7<br>after 5-FU<br>n=8 | WT mice<br>– day 7<br>after 5-FU<br>n=8 |
|--|--|-----------------------------|---|---|---|---|
| Blood<br>erythrocyte count<br>(x 10 <sup>12</sup> /l)              | 9.1 ± 0.15 <sup>##</sup>                         | 8.3 ± 0.12                  | 8.2 ± 0.27  | 8.2 ± 0.15                              | 6.5 ± 0.16  | 6.1 ± 0.18                              |
| Blood<br>hemoglobin level<br>(HGB) (g/l)                           | 132 ± 2.3 <sup>#</sup>                           | 125 ± 2.5                   | 117 ± 4.8   | 122 ± 2.0                               | 93 ± 2.6  | 91 ± 2.8                                |
| Hematocrit<br>(HCT) (%)  | 45.1 ± 0.91                                      | 43.0 ± 0.87                 | 39.7 ± 1.54   | 41.5 ± 0.78                             | 31.1 ± 0.89   | 30.7 ± 0.92                             |
| Mean<br>erythrocyte<br>volume (MCV)<br>(fl)                        | 50.0 ± 0.36**                                    | 51.8 ± 0.35                 | 48.7 ± 0.29***  | 50.7 ± 0.25                             | 48.0 ± 0.29***  | 50.9 ± 0.33                             |
| Mean<br>erythrocyte<br>hemoglobin<br>(MCH) (pg)                    | 14.6 ± 0.06**                                    | 15.1 ± 0.10                 | 14.4 ± 0.11***  | 14.9 ± 0.09                             | 14.3 ± 0.08***  | 15.0 ± 0.10                             |
| Mean<br>erythrocyte<br>hemoglobin<br>concentration<br>(MCHC) (g/l) | 293 ± 1.0 <sup>#</sup>                           | 291 ± 0.5                   | 295 ± 1.5   | 294 ± 1.0                               | 299 ± 1.2   | 295 ± 1.4                               |
| Red cell<br>distribution<br>width (RDW) (%)                        | 11.9 ± 0.18**                                    | 13.0 ± 0.26                 | 12.2 ± 0.34   | 12.4 ± 0.14                             | 11.7 ± 0.26   | 12.1 ± 0.28                             |

The results are presented as arithmetic means ± standard errors of the means (SEM). n = numbers of mice. \*\*, \*\*\* the value in A<sub>3</sub>AR KO mice is statistically significantly lower (P≤0.01, P≤0.001, respectively) than that in the corresponding WT counterparts. #, ## the value in A<sub>3</sub>AR KO mice is statistically significantly higher (P≤0.05, P≤0.01, respectively) than that in the corresponding WT counterparts.

**Table 3.** Values of peripheral blood platelet parameters in untreated, 5-fluorouracil (5-FU)-treated (day 2 after treatment), and 5-FU-treated (day 7 after treatment) adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) and wild-type (WT) mice.

| Parameter                                | Untreated A <sub>3</sub> AR KO mice<br>n=6 | Untreated WT mice<br>n=6 | A <sub>3</sub> AR KO mice – day 2 after 5-FU<br>n=9 | WT mice – day 2 after 5-FU<br>n=9 | A <sub>3</sub> AR KO mice – day 7 after 5-FU<br>n=8 | WT mice – day 7 after 5-FU<br>n=8 |
|--|--|--------------------------|---|-----------------------------------|---|-----------------------------------|
| Blood platelet count ( $\times 10^9/l$ ) | 987 $\pm$ 44.8                             | 1060 $\pm$ 57.0          | 882 $\pm$ 52.9**                                    | 1029 $\pm$ 26.8                   | 667 $\pm$ 57.4                                      | 609 $\pm$ 79.1                    |
| Mean platelet volume (MPV) (fl)          | 4.8 $\pm$ 0.02**                           | 5.5 $\pm$ 0.05           | 4.9 $\pm$ 0.09**                                    | 5.3 $\pm$ 0.04                    | 5.7 $\pm$ 0.11**                                    | 6.5 $\pm$ 0.13                    |
| Plateletcrit (PCT) (%)                   | 0.48 $\pm$ 0.022**                         | 0.59 $\pm$ 0.032         | 0.43 $\pm$ 0.027***                                 | 0.54 $\pm$ 0.013                  | 0.37 $\pm$ 0.030                                    | 0.40 $\pm$ 0.056                  |
| Platelet distribution width (PDW) (%)    | 14.6 $\pm$ 0.04**                          | 15.0 $\pm$ 0.03          | 14.6 $\pm$ 0.09*                                    | 14.8 $\pm$ 0.04                   | 15.3 $\pm$ 0.09*                                    | 15.6 $\pm$ 0.08                   |

The results are presented as arithmetic means  $\pm$  standard errors of the means (SEM). n = numbers of mice. \*, \*\*, \*\*\* the value in A<sub>3</sub>AR KO mice is statistically significantly lower ( $P \leq 0.05$ ,  $P \leq 0.01$ ,  $P \leq 0.001$ , respectively) than that in the corresponding WT counterparts.

**Table 4.** Values of femoral bone marrow parameters in untreated, 5-fluorouracil (5-FU)-treated (day 2 after treatment), and 5-FU-treated (day 7 after treatment) adenosine A<sub>3</sub> receptor knock-out (A<sub>3</sub>AR KO) and wild-type (WT) mice.

| Parameter   | Untreated A <sub>3</sub> AR KO mice<br>n=6 | Untreated WT mice<br>n=6 | A <sub>3</sub> AR KO mice – day 2 after 5-FU<br>n=9 | WT mice – day 2 after 5-FU<br>n=9 | A <sub>3</sub> AR KO mice – day 7 after 5-FU<br>n=8 | WT mice – day 7 after 5-FU<br>n=8 |
|---|--|--------------------------|---|-----------------------------------|---|-----------------------------------|
| Femoral bone marrow cellularity / g body weight ( $\times 10^3$ ) | 1.42 $\pm$ 0.067 <sup>##</sup>             | 1.08 $\pm$ 0.069         | 0.64 $\pm$ 0.039 <sup>##</sup>                      | 0.46 $\pm$ 0.037                  | 0.45 $\pm$ 0.032                                    | 0.42 $\pm$ 0.075                  |
| GM-CFC / femur / g body weight                                    | 598 $\pm$ 67.5                             | 426 $\pm$ 43.7           | 25.0 $\pm$ 4.23                                     | 19.7 $\pm$ 5.21                   | 344 $\pm$ 33.0 <sup>#</sup>                         | 230 $\pm$ 33.4                    |
| BFU-E / femur / g body weight                                     | 584 $\pm$ 79.5 <sup>##</sup>               | 400 $\pm$ 25.7           | 42.1 $\pm$ 5.10                                     | 23.6 $\pm$ 5.58                   | 188 $\pm$ 18.2                                      | 136 $\pm$ 20.7                    |

The results are presented as arithmetic means  $\pm$  standard errors of the means (SEM). n = numbers of mice. #, ## value in A<sub>3</sub>AR KO mice is statistically significantly higher ( $P \leq 0.05$ ,  $P \leq 0.01$ , respectively) than that in the corresponding WT counterparts.

#### Peripheral blood platelet parameters

Parameters concerning the peripheral blood platelets are shown in Table 3. Generally, a decline in the platelet parameters in the A<sub>3</sub>AR KO mice can be stated. While the blood platelet count in these mice was found to be significantly lower in one comparison (day 2 after the administration of 5-FU), the parameters of MPV and PDW were significantly decreased in all three comparisons, and that of PCT in untreated mice and on day 2 after the administration of 5-FU.

#### Bone marrow parameters

On the other hand, an activation of hematopoiesis, as assessed by the femoral bone marrow parameters (Table 4) was observed. The femoral bone marrow cellularity was observed to be significantly higher in untreated A<sub>3</sub>AR KO mice. In the A<sub>3</sub>AR KO mice, the numbers of femoral granulocyte-macrophage progenitor cells (GM-CFC) were found to be significantly higher on day 7 after the administration of 5-FU and those of erythroid progenitor cells (BFU-E) in

untreated mice. The approach of block comparison of the A<sub>3</sub>AR KO mice and their WT counterparts in the parameters of femoral GM-CFC and BFU-E revealed significantly higher values in the knock-out mice (P=0.001 and P<0.001, respectively).

*Comparison of the 5-FU-induced damage and subsequent regeneration between A<sub>3</sub>AR KO mice and their WT counterparts*

The magnitude of 5-FU-induced damage to selected hematopoietic parameters (neutrophil, lymphocyte, monocyte, eosinophil, erythrocyte, and thrombocyte peripheral blood counts, femoral bone marrow cellularity, and the numbers of femoral GM-CFC and BFU-E) was evaluated as the rate of decrease between the values of these parameters in untreated mice and those found on day 2 after the administration of 5-FU. The ability of the mice to regenerate from the 5-FU-induced damage was assessed as the rate of increase between the values found on days 2 and 7 after the administration of 5-FU. The rates of decrease or increase were calculated as ratios of the values between which the decreases or increases take part. Significant differences in this indicator between the A<sub>3</sub>AR KO mice and their WT counterparts were obtained nearly exclusively for the parameters of the femoral marrow progenitor cells. A significantly higher rate of decrease between the control state and day 2 after the administration of 5-FU was found in the A<sub>3</sub>AR KO mice both for the femoral GM-CFC and BFU-E (P=0.01, P=0.004, respectively). The rate of increase between the states on days 2 and 7 was calculated to be significantly higher in the A<sub>3</sub>AR KO mice in the parameter of the femoral GM-CFC (P=0.037). Besides these findings in the marrow progenitor cell compartments only one more significantly different rate of increase between days 2 and 7 was found, namely in the parameter of the blood platelet count, where the rate of increase was significantly higher in the A<sub>3</sub>AR KO mice (P=0.022).

## Discussion

The findings in the peripheral blood parameters have confirmed previous observations (Hofer *et al.* 2013a, 2014a) on the existence of defects in functional properties of erythrocytes and thrombocytes in the A<sub>3</sub>AR KO mice, as seen from the parameters of the mean erythrocyte volume, mean erythrocyte hemoglobin, and mean platelet volume (see Tables 2 and 3). Whether these

particular findings reflect also in an aggravation of the parameters like oxygen transport capacity, arterial pO<sub>2</sub>, or platelet aggregation test, an additional experimentation is, however, needed. An also previously described (Hofer *et al.* 2014a) obvious increase in the numbers of the bone marrow hematopoietic progenitor cells, GM-CFC and BFU-E, in the A<sub>3</sub>AR KO mice, explainable as an attempt of the hematopoietic system of these mice to compensate for the peripheral blood cell insufficiency, was observed in this study (see Table 4). In the erythroid compartment, the probable compensatory activity in the A<sub>3</sub>AR KO mice was apparently successful, as follows from their significantly higher blood erythrocyte count and blood hemoglobin level (see Table 2).

A sufficient number of the A<sub>3</sub>AR KO mice available for this study enabled to analyze the state of hematopoiesis in two time intervals following the administration of the cytotoxic drug, 5-FU, namely on days 2 and 7 after the 5-FU administration. These two time intervals can be designated as the time intervals of the states of damage and regeneration. The analyses performed for the processes of damage (decrease between control mice and those on day 2 after the administration of 5-FU) and regeneration (increase between days 2 and 7 after the administration of 5-FU) enabled us to compare the kinetics of these processes in the A<sub>3</sub>AR KO mice and their WT counterparts. The results of these analyses have shown that the expectably most sensitive compartments of the bone marrow progenitor cells, GM-CFC and BFU-E, are significantly more affected in the A<sub>3</sub>AR KO mice than in the WT mice, as follows from the significantly higher rate of decrease in these parameters in the KO mice. This finding suggests that there exists yet another hematopoietic defect caused by the lack of adenosine A<sub>3</sub> receptors than those hitherto observed in the peripheral blood cell parameters of the A<sub>3</sub>AR KO mice. The mechanism of the origin of this defect responsible for a higher susceptibility of the hematopoietic progenitor cells to the 5-FU-induced damage remains to be investigated.

The studies performed on the hematopoiesis of the A<sub>3</sub>AR KO mice so far have not comprised the parameter of the hematopoietic stem cells. However, recent investigations in normal mice have not demonstrated any efficacy of the administration of IB-MECA, an adenosine A<sub>3</sub> receptor agonist on the hematopoietic stem cell compartment (Hofer *et al.* 2013b).

A more general information about the overall health state of the A<sub>3</sub>AR KO mice could be provided by survival studies. The up to now performed numerous

experiments on the survival of normal mice after lethal irradiation and an adenosine A<sub>3</sub> receptor agonist administration have revealed an efficacy of the therapeutic intervention only if the agonist was given very early after administration (Hofer *et al.* 2014b). Several other administration schedules of the agonist, including its repeated administration, did not reveal any efficacy on post-irradiation survival of experimental mice (Hofer *et al.* 2012). Since post-irradiation survival is closely associated with the overall hematological state, survival studies might provide a significant piece of information on the ability of the hematopoietic system of the A<sub>3</sub>AR KO mice to cope with the lack of the adenosine A<sub>3</sub> receptor.

The adenosine A<sub>3</sub> receptor and its agonists have been in the midst of attention due to a number of indications including, e.g., those of cardiovascular (Hussain *et al.* 2014) or oncological diseases (Antonioli *et al.* 2013). Their involvement in the processes of hematopoiesis, as well as in hematological diseases and

their therapy, has been rather neglected by the majority of laboratories dealing with this general topic. However, recent findings on the efficacy of adenosine receptor agonists in the modulation of hematopoiesis obtained predominantly by the authors highlight the significance of adenosine A<sub>3</sub> receptors in hematopoiesis and their possible employment in clinical practice. Investigations in the A<sub>3</sub>AR KO mice represent a promising tool in the research on the mechanisms through which adenosine and further agonists of its receptors execute their roles in hematopoietic regulation processes.

### Conflict of Interest

There is no conflict of interest.

### Acknowledgements

The authors thank the Merck Research Laboratories (West Point, PA, USA) for providing us with A<sub>3</sub>AR KO mice. This work was supported by the Grant Agency of the Czech Republic (grant No. P303/11/0128).

### References

- ABBRACCHIO MP, BURNSTOCK G: Purinergic signalling: pathophysiological roles. *Jap J Pharmacol* **78**: 113-145, 1998.
- ANTONIOLI L, BLANDIZZI C, PACHER P, HASKÓ G: Immunity, inflammation and cancer: a leading role for adenosine. *Nature Rev Cancer* **13**: 842-857, 2013.
- FREDHOLM BB, ARSLAN G, HALLDNER L, KULL B, SCHULTE G, ÅDÉN U, SVENNINGSSON P: Adenosine receptor signaling *in vitro* and *in vivo*. *Drug Dev Res* **52**: 274-282, 2001.
- HOFER M, POSPÍŠIL M: Role of adenosine signaling in hematopoiesis – a short review. *Med Hypotheses Res* **3**: 629-635, 2006.
- HOFER M, POSPÍŠIL M, NETÍKOVÁ J, ZNOJIL V, VÁCHA J, HOLÁ J: Radioprotective efficacy of dipyrindamole and AMP combination in fractionated radiation regimen, and its dependence on the time of administration of the drugs prior to irradiation. *Physiol Res* **44**: 93-98, 1995.
- HOFER M, POSPÍŠIL M, NETÍKOVÁ J, ZNOJIL V, VÁCHA J: Enhancement of haematopoietic spleen colony formation by drugs elevating extracellular adenosine. Effects of repeated *in vivo* treatment. *Physiol Res* **46**: 285-290, 1997.
- HOFER M, POSPÍŠIL M, WEITEROVÁ L, ZNOJIL V, VÁCHA J, HOLÁ J, VACEK A, PIPALOVÁ I: Combination of drugs elevating extracellular adenosine with granulocyte colony-stimulating factor promotes granulopoietic recovery in mouse bone marrow after 5-fluorouracil treatment. *Physiol Res* **50**: 521-524, 2001.
- HOFER M, POSPÍŠIL M, VACEK A, HOLÁ J, ZNOJIL V, WEITEROVÁ L, ŠTREITOVÁ D: Effects of adenosine A<sub>3</sub> receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice. *Eur J Pharmacol* **538**: 163-167, 2006.
- HOFER M, POSPÍŠIL M, ŠEFC L, DUŠEK L, VACEK A, HOLÁ J, HOFEROVÁ Z, ŠTREITOVÁ D: Activation of adenosine A<sub>3</sub> receptors supports hematopoiesis-stimulating effects of granulocyte colony-stimulating factor in sublethally irradiated mice. *Int J Radiat Biol* **86**: 649-656, 2010.
- HOFER M, DUŠEK L, HOFEROVÁ Z, STIXOVÁ L, POSPÍŠIL M: Expression of mRNA for adenosine A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub>, and A<sub>3</sub> receptors in HL-60 cells: dependence on cell cycle phases. *Physiol Res* **60**: 913-920, 2011a.

- HOFER M, POSPÍŠIL M, WEITEROVÁ L, HOFEROVÁ Z: The role of adenosine receptor agonists in regulation of hematopoiesis. *Molecules* **16**: 675-685, 2011b.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, KOMŮRKOVÁ D: IB-MECA, an adenosine A<sub>3</sub> receptor agonist, does not influence survival of lethally  $\gamma$ -irradiated mice. *Physiol Res* **61**: 649-654, 2012.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, WEITEROVÁ L, KOMŮRKOVÁ D: Erythropoiesis- and thrombopoiesis-characterizing parameters in adenosine A<sub>3</sub> receptor knock-out mice. *Physiol Res* **62**: 305-311, 2013a.
- HOFER M, POSPÍŠIL M, HOFEROVÁ Z, KOMŮRKOVÁ D, PÁRAL P, SAVVULIDI F, ŠEFC L: The pharmacological activation of adenosine A<sub>1</sub> and A<sub>3</sub> receptors does not modulate the long- or short-term repopulating ability of hematopoietic stem and multipotent progenitor cells in mice. *Purinergic Signal* **9**: 207-214, 2013b.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, KOMŮRKOVÁ D: Lack of adenosine A<sub>3</sub> receptors causes defects in mouse peripheral blood parameters. *Purinergic Signal* **10**: 509-514, 2014a.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, KOMŮRKOVÁ D: Agonist of the adenosine A<sub>3</sub> receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of  $\gamma$ -irradiated mice. *Radiat Environ Biophys* **53**: 211-215, 2014b.
- HUSSAIN A, GHARANEI AM, NAGRA AS, MADDOCK HL: Caspase inhibition via A<sub>3</sub> adenosine receptors: a new cardioprotective mechanism against myocardial infarction. *Cardiovasc Drug Ther* **28**: 19-32, 2014.
- JACOBSON KA, HOFFMAN C, CATTABENI F, ABBRACCHIO MP: Adenosine-induced cell death: evidence for receptor-mediated signalling. *Apoptosis* **4**: 197-211, 1999.
- JACOBSON MA: Adenosine receptor agonists. *Expert Opin Ther Patents* **12**: 489-501, 2002.
- KLOTZ K-N: Adenosine receptors and their ligands. *Naunyn-Schmied Arch Pharmacol* **362**: 382-391, 2000.
- MERIMSKY O, BAR-YEHUDA S, MADI L, FISHMAN P: Modulation of the adenosine A<sub>3</sub> receptor by low agonist concentration induces antitumor and myelostimulatory effects. *Drug Dev Res* **58**: 386-389, 2003.
- POSPÍŠIL M, HOFER M, NETÍKOVÁ J, VIKLICKÁ Š, PIPALOVÁ I, BARTONÍČKOVÁ A: Effect of dipyridamole and adenosine monophosphate on cell proliferation in the hemopoietic tissue of normal and gamma-irradiated mice. *Experientia* **48**: 253-257, 1992.
- POSPÍŠIL M, HOFER M, VACEK A, NETÍKOVÁ J, PIPALOVÁ I, VIKLICKÁ Š: Noradrenaline reduces cardiovascular effects of the combined dipyridamole and AMP administration but preserves radioprotective effects of these drugs on hematopoiesis in mice. *Physiol Res* **42**: 333-340, 1993.
- POSPÍŠIL M, HOFER M, VACEK A, ZNOJIL V, PIPALOVÁ I: Effects of stable adenosine receptor agonists on bone marrow hematopoietic cells as inferred from the cytotoxic action of 5-fluorouracil. *Physiol Res* **53**: 549-556, 2004.
- POULSEN S-A, QUINN RJ: Adenosine receptors: new opportunities for future drugs. *Bioorgan Med Chem* **6**: 619-641, 1998.
- SALVATORE CA, TILLEY SL, LATOUR AM, FLETCHER DS, KOLLER BH, JACOBSON MA: Disruption of the A<sub>3</sub> adenosine receptor gene in mice and its effect on stimulated inflammatory cells. *J Biol Chem* **275**: 4429-4434, 2000.
- SCHULTE G, FREDHOLM BB: Signalling from adenosine receptors to mitogen-activated protein kinases. *Cell Signal* **15**: 813-827, 2003.
- ŠTREITOVÁ D, ŠEFC L, SAVVULIDI F, POSPÍŠIL M, HOLÁ J, HOFER M: Adenosine A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub>, and A<sub>3</sub> receptors in hematopoiesis. 1. Expression of receptor mRNA in four mouse hematopoietic precursor cells. *Physiol Res* **59**: 133-137, 2010.
- WEITEROVÁ L, HOFER M, POSPÍŠIL M, ZNOJIL V, VÁCHA J, VACEK A, PIPALOVÁ I: Influence of the joint treatment with granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on erythropoietic recovery following 5-fluorouracil-induced haematotoxicity in mice. *Eur J Haematol* **65**: 310-316, 2000.